Substance / Medication

Norethisterone

Overview

Active Ingredient
norethindrone
RxNorm CUI
7514
Labeler: Glenmark Pharmaceuticals Inc., USAUpdated: 2026-01-31T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Progestin-only oral contraceptives (POPs) should not be used by women who currently have the following conditions: • Known or suspected pregnancy • Known or suspected carcinoma of the breast. • Undiagnosed abnormal genital bleeding • Hypersensitivity to any component of this product • Benign or mali

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

153 trials linked to this intervention

153
Total Trials
11
Recruiting
80
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The effect of 17beta-estradiol plus norethisterone acetate on anthropometric indices: A systematic review and meta-analysis of randomized controlled trials.
Li Yushan, Chen Xiao, Gong Xingji et al. · Eur J Obstet Gynecol Reprod Biol · 2023
PMID: 37364427Meta-Analysis
The effect of 17β-estradiol plus norethisterone acetate on blood pressure and inflammation markers: A meta-analysis of randomized controlled trials.
Liu Hong, Zhan Jiang, He Jiao et al. · Eur J Obstet Gynecol Reprod Biol · 2023
PMID: 37060841Meta-Analysis
The effect of 17β-estradiol plus norethisterone acetate treatment on the lipid profile in women: a dose-response meta-analysis of randomized controlled trials.
Abu-Zaid Ahmed, Gaman Mihnea-Alexandru, Jamilian Parsa et al. · Exp Gerontol · 2022
PMID: 35640782Meta-Analysis
When can a woman have repeat progestogen-only injectables--depot medroxyprogesterone acetate or norethisterone enantate?
Paulen Melissa E, Curtis Kathryn M · Contraception · 2009
PMID: 19751863Meta-Analysis
Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception.
Draper B H, Morroni C, Hoffman M et al. · Cochrane Database Syst Rev · 2006
PMID: 16856087Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Norethisterone (substance)
SNOMED CT
126102009
UMLS CUI
C0028356
RxNorm CUI
7514
Labeler
Glenmark Pharmaceuticals Inc., USA

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

4
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
153
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.